According to Archimedes Pharma, the Scottish Medicines Consortium has approved the company’s PecFent fentanyl pectin nasal spray for the treatment of breakthrough cancer pain for use in NHS Scotland. The product received marketing authorization in the European Union in September 2010 and is under review by the FDA for use in the US. Read the company’s press release.
PecFent nasal spray approved for use in Scottish national health system
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
